Methods of treating graft rejection or reducing risk of graft rejection

• Main Authors: MOCHUDDIN MOHAMMAD M, PAOLINI, JOHN, F
• Format: Patent
• Language: Chinese; English
• Published: 01.11.2024
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present disclosure relates to methods of treating graft rejection in a subject (e.g., a human) in need thereof, or reducing the risk of graft rejection in the subject, or increasing the duration prior to developing graft rejection in the subject, by administering an antagonist targeting CD40 or CD154, such as an anti-CD40 antibody or antigen-binding fragment thereof (e.g., an antigen-binding fragment thereof), to the subject, or reducing the risk of graft rejection in the subject, or increasing the duration prior to developing graft rejection in the subject. And a humanized anti-CD40 antibody or an antigen-binding fragment thereof). The graft may be an allograft or a xenograft (e.g., a cell, tissue, or organ or portion thereof). 本公开涉及通过以下治疗有需要的受试者(例如，人)的移植物排斥或降低所述受试者的移植物排斥风险或增加在所述受试者体内发生移植物排斥之前的持续时间的方法：施用靶向CD40或CD154的拮抗剂，如抗CD40抗体或其抗原结合片段(例如，人源化抗CD40抗体或其抗原结合片段)。移植物可以是同种异体或异种移植物(例如，细胞、组织、或器官或其部分)。